1330 related articles for article (PubMed ID: 29649510)
21. Analysis of the Expression and Function of Immunoglobulin-Like Transcript 4 (ILT4, LILRB2) in Dendritic Cells from Patients with Systemic Lupus Erythematosus.
Guerra-de Blas Pdel C; Villaseñor-Talavera YS; Cruz-González Dde J; Baranda L; Doníz-Padilla L; Abud-Mendoza C; González-Amaro R; Monsiváis-Urenda AE
J Immunol Res; 2016; 2016():4163094. PubMed ID: 27057555
[TBL] [Abstract][Full Text] [Related]
22. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
23. Recent progress in therapeutic antibodies for cancer immunotherapy.
Lee A; Sun S; Sandler A; Hoang T
Curr Opin Chem Biol; 2018 Jun; 44():56-65. PubMed ID: 29885949
[TBL] [Abstract][Full Text] [Related]
24. The Expression of ILT4 in Myeloid Dendritic Cells in Patients with Hepatocellular Carcinoma.
Wang L; Fan J; Ye W; Han J; Zhang Y; Zhao L; Duan J; Yin D; Yi Y
Immunol Invest; 2019 Oct; 48(7):704-718. PubMed ID: 31044626
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
Wilky BA
Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
[TBL] [Abstract][Full Text] [Related]
26. Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy.
Park SY; Kim IS
Cancer Lett; 2019 Jun; 452():51-58. PubMed ID: 30910590
[TBL] [Abstract][Full Text] [Related]
27. Current status of immunotherapy.
Suzuki S; Ishida T; Yoshikawa K; Ueda R
Jpn J Clin Oncol; 2016 Mar; 46(3):191-203. PubMed ID: 26819277
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint modulators in cancer immunotherapy: Recent advances and combination rationales.
Fan L; Li Y; Chen JY; Zheng YF; Xu XM
Cancer Lett; 2019 Aug; 456():23-28. PubMed ID: 30959079
[TBL] [Abstract][Full Text] [Related]
29. Role of immunolglobulin-like transcript family receptors and their ligands in suppressor T-cell-induced dendritic cell tolerization.
Chui CS; Li D
Hum Immunol; 2009 Sep; 70(9):686-91. PubMed ID: 19524004
[TBL] [Abstract][Full Text] [Related]
30. The expression and function of immunoglobulin-like transcript 4 in dendritic cells from patients with hepatocellular carcinoma.
Fan J; Han J; Li J; Gu A; Yin D; Song F; Wang L; Yi Y
Hum Immunol; 2020 Dec; 81(12):714-725. PubMed ID: 33228921
[TBL] [Abstract][Full Text] [Related]
31. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
Adachi K; Tamada K
Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
[TBL] [Abstract][Full Text] [Related]
33. Combination cancer immunotherapies tailored to the tumour microenvironment.
Smyth MJ; Ngiow SF; Ribas A; Teng MW
Nat Rev Clin Oncol; 2016 Mar; 13(3):143-58. PubMed ID: 26598942
[TBL] [Abstract][Full Text] [Related]
34. Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25+ Foxp3+ T regulatory cells.
Brenk M; Scheler M; Koch S; Neumann J; Takikawa O; Häcker G; Bieber T; von Bubnoff D
J Immunol; 2009 Jul; 183(1):145-54. PubMed ID: 19535644
[TBL] [Abstract][Full Text] [Related]
35. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoint inhibitors for cancer treatment.
Park J; Kwon M; Shin EC
Arch Pharm Res; 2016 Nov; 39(11):1577-1587. PubMed ID: 27770382
[TBL] [Abstract][Full Text] [Related]
37. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue Y; Nishikawa H
Cancer Sci; 2019 Jul; 110(7):2080-2089. PubMed ID: 31102428
[TBL] [Abstract][Full Text] [Related]
38. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
39. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
40. [The "immune checkpoints", how does it work].
Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]